Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Retained Earnings (2021 - 2025)

Historic Retained Earnings for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $24.2 million.

  • Krystal Biotech's Retained Earnings rose 11339.47% to $24.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $24.2 million, marking a year-over-year increase of 11339.47%. This contributed to the annual value of $24.2 million for FY2025, which is 11339.47% up from last year.
  • According to the latest figures from Q4 2025, Krystal Biotech's Retained Earnings is $24.2 million, which was up 11339.47% from -$27.2 million recorded in Q3 2025.
  • Krystal Biotech's 5-year Retained Earnings high stood at $24.2 million for Q4 2025, and its period low was -$359.3 million during Q2 2023.
  • In the last 5 years, Krystal Biotech's Retained Earnings had a median value of -$204.8 million in 2022 and averaged -$190.3 million.
  • In the last 5 years, Krystal Biotech's Retained Earnings tumbled by 11918.62% in 2022 and then surged by 11339.47% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Retained Earnings stood at -$140.8 million in 2021, then tumbled by 99.43% to -$280.8 million in 2022, then rose by 3.89% to -$269.8 million in 2023, then skyrocketed by 33.04% to -$180.7 million in 2024, then surged by 113.39% to $24.2 million in 2025.
  • Its Retained Earnings was $24.2 million in Q4 2025, compared to -$27.2 million in Q3 2025 and -$106.6 million in Q2 2025.